\
&
Contact us
\
&
Contact us
This was 6 years ago
LocationOnline
The FOSTER+ project (Fostering the practical implementation of Open Science in Horizon 2020 and beyond) has received funding under the Horizon 2020 programme Swafs (Science with and for Society).
On 18 June the project organises a webinar on 'Open Science & Open Innovation: Synergies and Conflicts':
'Is disclosure of research in conflict with traditional IPR practices? Are both concepts mutually exclusive? And how should young researchers navigate these uncertain waters as funders request more disclosure and more commercialisation at the same time?
What are the synergies between Open Science & IPR, and what are the basic "rules of thumb" that will equip young researchers to confidently master both practices for optimal societal impact?
These are some of the academia-industry questions that will be explored in a series of webinars over the summer months, in order to support young researchers everywhere, Marie Curie applicants for 11 September 2019, as well as all scientists with an open mind.'
Please register for the webinar here
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space AI Continent Semiconductors
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
